Table 2 Clinical characteristics of the non-responder and responder groups.
From: Booster effect of the third dose of SARS-CoV-2 mRNA vaccine in Japanese kidney transplant recipients
Variable | IgG S antibody Non-responders (N = 20) | IgG S antibody Responders (N = 62) | P-value |
|---|---|---|---|
Age, year | 55.0 ± 9.0 | 53.1 ± 12.4 | 0.52 |
Sex, male, n (%) | 12 (60.0) | 41 (66.1) | 0.62 |
Body mass index, kg/m2 | 21.5 ± 3.8 | 23.0 ± 3.3 | 0.07 |
Time post last transplantation, year | 4.2 (1.7 to 11.5) | 11.7 (7.8 to 16.6) | 0.006 |
First transplant, n (%) | 18 (90.0) | 61 (98.4) | 0.08 |
Donor type, living, n (%) | 20 (100.0) | 53 (85.5) | 0.07 |
Donor age, year | 63.5 (57.5 to 69.5) | 55.0 (45.5 to 61.5) | 0.0003 |
Donor sex, male, n (%) | 5 (25.0) | 23 (40.4) | 0.22 |
Primary kidney disease | 0.28 | ||
IgA nephrology | 10 (50.0) | 17 (27.4) | |
FSGS | 2 (10.0) | 5 (8.1) | |
Diabetes mellitus | 1 (5.0) | 3 (4.8) | |
Others | 7 (35.0) | 37 (59.7) | |
ABO incompatible, n (%) | 2 (10.0) | 11 (17.7) | 0.68 |
HLA class I mismatch | 1.8 ± 0.6 | 1.7 ± 1.0 | 0.93 |
HLA class II mismatch | 0.9 ± 0.5 | 0.9 ± 0.5 | 0.77 |
Rituximab use, n (%) | 6 (30.0) | 18 (29.0) | 0.93 |
Methylprednisolone use, n (%) | 20 (100.0) | 48 (77.4) | 0.02 |
Tacrolimus use, n (%) | 17 (85.0) | 54 (87.1) | 0.81 |
Tacrolimus trough concentration | 3.9 (3.2 to 4.9) | 4.0 (3.2 to 5.0) | 0.70 |
Mycophenolic acid dose, mg/day | 1225.0 ± 404.7 | 899.2 ± 425.8 | 0.004 |
Methylprednisolone + Tacrolimus + Mycophenolic acid, n (%) | 16 (80.0) | 42 (67.7) | 0.30 |
Hemoglobin, g/dL | 11.9 ± 1.3 | 13.5 ± 2.0 | 0.001 |
Lymphocyte, /μL | 955.0 ± 424.9 | 1674.2 ± 639.7 | < 0.0001 |
Albumin, g/dL | 4.1 ± 0.4 | 4.2 ± 0.3 | 0.40 |
Serum creatinine, mg/dL | 1.7 (1.1 to 2.7) | 1.2 (0.9 to 1.5) | 0.03 |
eGFR, mL/min/m2 | 34.6 ± 14.4 | 48.2 ± 16.6 | 0.002 |
TSAT, % | 33.3 ± 13.7 | 32.4 ± 11.3 | 0.78 |
Ferritin, ng/mL | 123.0 (90.5 to 151.0) | 119.0 (52.0 to 205.0) | 1.00 |
25(OH)D, ng/mL | 15.7 (10.3 to 21.1) | 14.9 (10.7 to 22.2) | 0.73 |
Iron drug use, n (%) | 9 (45.0) | 4 (6.5) | < 0.001 |
1α-OH-D3 drug use, n (%) | 14 (70.0) | 19 (30.7) | 0.002 |
Hypertension, n (%) | 13 (65.0) | 43 (69.4) | 0.72 |
Diabetes mellitus, n (%) | 4 (20.0) | 17 (27.4) | 0.51 |
ACE-I or ARB use, n (%) | 10 (50.0) | 37 (59.7) | 0.45 |
Rejection, n (%) | 6 (30.0) | 15 (24.2) | 0.61 |
Twice Vaccine type, mRNA-1273 vs BNT162b2, n (%) | 0(0) vs 20 (100) | 12 (19.4) vs 50 (80.7) | 0.03 |
Third Vaccine type, mRNA-1273 vs BNT162b2, n (%) | 6 (30.0) vs 14 (70.0) | 33 (53.2) vs 29 (46.8) | 0.07 |
